Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma.
作者： Danielle A Murphy , Brian I Rini , Bernard Escudier , Robert J Motzer , Panpan Wang
关键词:
摘要: Aim: Immunomodulatory mechanisms contributing to angiogenic inhibition in renal tumors are not well characterized. We report associations between efficacy and tumor-associated immune cells mRNA/miRNA expression patients from AXIS. Materials & methods: Immunohistochemistry (n = 52) analyses 72) were performed on tumor samples. Results: In axitinib-treated patients, higher CXCR4 TLR3 expression, respectively, was associated with longer progression-free survival (hazard ratio; 95% CI: 0.3; 0.1-0.8 0.4; 0.2-0.9) showed interaction treatment (p 0.029 p < 0.001); lower CCR7 objective response (odds ratio: 0.1; 0.01-1.0) overall 3.9; 1.4-10.3). Conclusion: CCR7, levels may be prognostic/predictive of clinical benefit axitinib. Clinical trial identifier: ClinicalTrials.gov NCT00678392.
scilit.net参考文章(37)
Mikko Mella, Joonas H Kauppila, Peeter Karihtala, Petri Lehenkari, Arja Jukkola-Vuorinen, Ylermi Soini, Päivi Auvinen, Markku H Vaarala, Hanna Ronkainen, Saila Kauppila, Kirsi-Maria Haapasaari, Katri S Vuopala, Katri S Selander, Tumor infiltrating CD8+ T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinoma OncoImmunology. ,vol. 4, ,(2015) , 10.1080/2162402X.2014.1002726
Bruno Salaun, Isabelle Coste, Marie-Clotilde Rissoan, Serge J. Lebecque, Toufic Renno, TLR3 can directly trigger apoptosis in human cancer cells. Journal of Immunology. ,vol. 176, pp. 4894- 4901 ,(2006) , 10.4049/JIMMUNOL.176.8.4894
Yann Christinat, Wilhelm Krek, Integrated genomic analysis identifies subclasses and prognosis signatures of kidney cancer Oncotarget. ,vol. 6, pp. 10521- 10531 ,(2015) , 10.18632/ONCOTARGET.3294
Hiroshi Toge, Takeshi Inagaki, Yasuo Kojimoto, Toshiaki Shinka, Isao Hara, Angiogenesis in renal cell carcinoma: The role of tumor-associated macrophages International Journal of Urology. ,vol. 16, pp. 801- 807 ,(2009) , 10.1111/J.1442-2042.2009.02377.X
Franziska Stehle, Kristin Schulz, Corinna Fahldieck, Jana Kalich, Rudolf Lichtenfels, Dagmar Riemann, Barbara Seliger, Reduced Immunosuppressive Properties of Axitinib in Comparison with Other Tyrosine Kinase Inhibitors Journal of Biological Chemistry. ,vol. 288, pp. 16334- 16347 ,(2013) , 10.1074/JBC.M112.437962
J. Lin, X. Sun, B. Feng, F. Jiang, G. Li, M.I. Chiu, B. Esteves, M. Al-Adhami, P. Bhargava, M.O. Robinson, 608 Tivozanib biomarker identifies tumor infiltrating myeloid cells contributing to tivozanib resistance in both preclinical models and human renal cell carcinoma Ejc Supplements. ,vol. 8, pp. 191- ,(2010) , 10.1016/S1359-6349(10)72315-6
Daniel F. Legler, Edith Uetz-von Allmen, Mark A. Hauser, CCR7: Roles in cancer cell dissemination, migration and metastasis formation The International Journal of Biochemistry & Cell Biology. ,vol. 54, pp. 78- 82 ,(2014) , 10.1016/J.BIOCEL.2014.07.002
Gabriele Bergers, Douglas Hanahan, Modes of resistance to anti-angiogenic therapy Nature Reviews Cancer. ,vol. 8, pp. 592- 603 ,(2008) , 10.1038/NRC2442
Nan Wang, Hongwei Liang, Ke Zen, Molecular Mechanisms That Influence the Macrophage M1–M2 Polarization Balance Frontiers in Immunology. ,vol. 5, pp. 614- 614 ,(2014) , 10.3389/FIMMU.2014.00614
Benoit Beuselinck, Sylvie Job, Etienne Becht, Alexandra Karadimou, Virginie Verkarre, Gabrielle Couchy, Nicolas Giraldo, Nathalie Rioux-Leclercq, Vincent Molinié, Mathilde Sibony, Reza Elaidi, Corinne Teghom, Jean-Jacques Patard, Arnaud Méjean, Wolf Herman Fridman, Catherine Sautès-Fridman, Aurélien de Reyniès, Stéphane Oudard, Jessica Zucman-Rossi, None, Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting Clinical Cancer Research. ,vol. 21, pp. 1329- 1339 ,(2015) , 10.1158/1078-0432.CCR-14-1128